ClinicalTrials.gg
CompletedNCT03320434Updated Oct 17, 2022Results posted

Study Evaluating the Efficacy and Safety of PRT-2761 for the Treatment of Acute and Chronic Allergic Conjunctivitis

A Phase 2 interventional study of PRT-2761 0.5% and PRT-2761 1% in Allergic Conjunctivitis, sponsored by ORA, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-10-17.

Sponsored by ORA, Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 95 studies in Conjunctivitis, Allergic with a site in United States — 6 open to participants now, 7 under way, 2 of them phase 3. Conjunctivitis, Allergic · United States.

Enrollment
34th of 90
120 · median 94
Started
2017
with 3 others
Phase 2
25 of 95
4 open now
Registered
67th of 95
by date
Lead sponsor
8 of 95
ORA, Inc.

Among the 95 studies in Conjunctivitis, Allergic with a site in United States, this one is the 34th largest by enrollment of the 90 interventional ones that give a count, is one of 4 that started in 2017, is one of 25 in phase 2, and was the 67th registered.

Conjunctivitis, Allergic

211 studies on the registry are indexed under Conjunctivitis, Allergic; 19 are open to participants now.

Browse Conjunctivitis, Allergic studies →

Open to participants now

6 of the 95 studies in Conjunctivitis, Allergic with a site in United States are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 12 Conjunctivitis, Allergic studies recruiting now, 8 (67%) set no upper age limit and 4 (33%) stop at 75 or younger; 4 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 95 studies in Conjunctivitis, Allergic with a site in United States, or all of them as a file.
02

Study summary

To evaluate the efficacy and safety of two concentrations of PRT-2761 as a topical ophthalmic solution for the treatment of the signs and symptoms of acute and chronic allergic conjunctivitis.

03

Conditions studied

  • Allergic Conjunctivitis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • be at least 18 years old
  • be willing and able to avoid all disallowed medications and contact lenses
  • must have a pregnancy test if of
  • must be able to read an eye chart from 10 feet away

Exclusion criteria

Exclusion Criteria:

  • must not have any allergies to the study medications
  • must not have any ocular or non ocular condition that investigator feels will interfere with study parameters
  • must not have used an drug or device in the past 30 days or concurrently enrolled in another investigational trial
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
120 participants (actual)

Study arms

  • Experimental
    PRT-2761 0.5%

    Drug: PRT-2761 0.5%

  • Experimental
    PRT-2761 1%

    Drug: PRT-2761 1%

  • Active comparator
    Patanol

    Drug: Patanol

  • Active comparator
    Pred-forte

    Drug: Pred-forte

  • Placebo comparator
    PRT-2761 0%

    Drug: PRT-2761 0%

Interventions

  • DrugPRT-2761 0.5%

    Six drops in each eye over a 17 day period.

  • DrugPRT-2761 1%

    Six drops in each eye over a 17 day period.

  • Six drops in each eye over a 17 day period.

  • Four drops in each eye over a 3 day period.

  • DrugPRT-2761 0%

    Six drops in each eye over a 17 day period.

06

What researchers measure

Primary outcomes

  1. Ocular Itching at 5, 7, and 10 Minutes Post CAC on Day 1

    Ocular Itching was assessed by a trained investigator post-conjunctival allergen challenge (CAC) on a 0 to 4 scale (0=none (best/no itching) to 4=severe (worst/most itching). The ocular itching was averaged across all subjects at each time point.

    Time frame: post CAC exposure at 5, 7, and 10 minutes post CAC on Day 1

  2. Ocular Itching at 5, 7, and 10 Minutes Post CAC on Day 15

    Ocular Itching was assessed by the subjects using a 0 to 4 point scale(0=none (best/no itching) to 4=severe (worst/most itching)). The ocular itching was averaged across all subjects at each time point.

    Time frame: post CAC exposure at 5, 7, and 10 minutes post CAC on Day 15

  3. Conjunctival Redness at 7, 15, and 20 Minutes Post CAC on Day 1

    Conjunctival Redness was assessed by a trained investigator post-conjunctival allergen challenge (CAC) on a 0 to 4 scale (0=none (best/no redness) to 4=severe (worst/most redness)). The conjunctival redness was averaged across all subjects at each time point.

    Time frame: post CAC exposure at 7, 15, and 20 minutes post-CAC on Day 1.

  4. Conjunctival Redness at 7, 15, and 20 Minutes Post CAC on Day 15

    Conjunctival Redness was assessed by a trained investigator post-conjunctival allergen challenge (CAC) on a 0 to 4 scale (0=none (best/no redness) to 4=severe (worst/most redness)). The conjunctival redness was averaged across all subjects at each time point.

    Time frame: post CAC exposure at 7, 15, and 20 minutes post-CAC on Day 15.

07

Results

Posted Oct 17, 2022

Participant flow

Subjects were recruited from one site in the US.

Participant flow — Overall Study
MilestonePRT-2761 0.5%PRT-2761 1%PatanolPRT-2761 0%
Started32293029
Completed25232823
Not completed7626

Outcome measures

PrimaryOcular Itching at 5, 7, and 10 Minutes Post CAC on Day 1

Ocular Itching was assessed by a trained investigator post-conjunctival allergen challenge (CAC) on a 0 to 4 scale (0=none (best/no itching) to 4=severe (worst/most itching). The ocular itching was averaged across all subjects at each time point.

Time frame:
post CAC exposure at 5, 7, and 10 minutes post CAC on Day 1
Reported as:
Mean · units on a scale
Ocular Itching at 5, 7, and 10 Minutes Post CAC on Day 1
units on a scalePRT-2761 0.5%PRT-2761 1%PatanolPRT-2761 0%
5 minutes post-CAC2.573 ± 0.92462.500 ± 0.77921.217 ± 0.88262.647 ± 0.8170
7 minutes post-CAC2.677 ± 0.88792.509 ± 0.81141.358 ± 0.86272.629 ± 0.7459
10 minutes post-CAC2.250 ± 1.08782.293 ± 1.01351.258 ± 0.97272.190 ± 0.8754
PrimaryOcular Itching at 5, 7, and 10 Minutes Post CAC on Day 15

Ocular Itching was assessed by the subjects using a 0 to 4 point scale(0=none (best/no itching) to 4=severe (worst/most itching)). The ocular itching was averaged across all subjects at each time point.

Time frame:
post CAC exposure at 5, 7, and 10 minutes post CAC on Day 15
Reported as:
Mean · units on a scale
Ocular Itching at 5, 7, and 10 Minutes Post CAC on Day 15
units on a scalePRT-2761 0.5%PRT-2761 1%PatanolPRT-2761 0%
5 minutes post-CAC2.431 ± 1.14152.611 ± 0.77310.775 ± 0.71722.527 ± 0.9288
7 minutes post-CAC2.362 ± 1.07242.602 ± 0.78830.808 ± 0.75052.366 ± 0.9317
10 minutes post-CAC1.922 ± 1.12422.204 ± 1.06300.833 ± 0.80771.929 ± 0.9425
PrimaryConjunctival Redness at 7, 15, and 20 Minutes Post CAC on Day 1

Conjunctival Redness was assessed by a trained investigator post-conjunctival allergen challenge (CAC) on a 0 to 4 scale (0=none (best/no redness) to 4=severe (worst/most redness)). The conjunctival redness was averaged across all subjects at each time point.

Time frame:
post CAC exposure at 7, 15, and 20 minutes post-CAC on Day 1.
Reported as:
Mean · units on a scale
Conjunctival Redness at 7, 15, and 20 Minutes Post CAC on Day 1
units on a scalePRT-2761 0.5%PRT-2761 1%PatanolPRT-2761 0%
7 minutes post-CAC1.282 ± 0.64791.491 ± 0.59191.592 ± 0.72361.957 ± 0.4913
15 minutes post-CAC1.411 ± 0.61421.526 ± 0.59891.833 ± 0.73502.181 ± 0.3774
20 minutes post-CAC1.371 ± 0.58411.603 ± 0.62511.917 ± 0.68332.164 ± 0.4496
PrimaryConjunctival Redness at 7, 15, and 20 Minutes Post CAC on Day 15

Conjunctival Redness was assessed by a trained investigator post-conjunctival allergen challenge (CAC) on a 0 to 4 scale (0=none (best/no redness) to 4=severe (worst/most redness)). The conjunctival redness was averaged across all subjects at each time point.

Time frame:
post CAC exposure at 7, 15, and 20 minutes post-CAC on Day 15.
Reported as:
Mean · units on a scale
Conjunctival Redness at 7, 15, and 20 Minutes Post CAC on Day 15
units on a scalePRT-2761 0.5%PRT-2761 1%PatanolPRT-2761 0%
7 minutes post-CAC1.723 ± 0.57872.056 ± 0.44581.242 ± 0.72961.973 ± 0.4731
15 minutes post-CAC1.920 ± 0.67032.176 ± 0.48941.617 ± 0.74781.991 ± 0.5464
20 minutes post-CAC1.857 ± 0.62892.222 ± 0.66991.592 ± 0.72662.036 ± 0.6372

Adverse events

Collected over Adverse events were collected through study completion, an average of 9 weeks. All subjects who received study medication were evaluable for the safety analysis.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
PRT-2761 0.5%0/32 (0%)0/32 (0%)4/32 (12.5%)
PRT-2761 1%0/29 (0%)0/29 (0%)9/29 (31%)
Patanol0/30 (0%)0/30 (0%)1/30 (3.3%)
PRT-2761 0%0/29 (0%)0/29 (0%)7/29 (24.1%)
Most frequent other events
Showing 10 of 19
Most frequent other events
EventPRT-2761 0.5%PRT-2761 1%PatanolPRT-2761 0%
Visual Acuity ReducedEye disorders0/323/290/301/29
Conjunctival HaemorrhageEye disorders0/321/290/300/29
Conjunctival PigmentationEye disorders0/321/290/300/29
Corneal OpacityEye disorders0/320/290/301/29
Dry EyeEye disorders0/320/290/301/29
Eye DischargeEye disorders0/320/290/301/29
Eyelid OedemaEye disorders0/321/290/300/29
Meibomian Gland DysfunctionEye disorders0/320/290/301/29
Retinal HaemorrhageEye disorders0/321/290/300/29
DiarrhoeaGastrointestinal disorders0/321/290/300/29

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)PRT-2761 0.5%PRT-2761 1%PatanolPRT-2761 0%Total
<=18 years00000
Between 18 and 65 years30273027114
>=65 years22026
Age, Continuous
Age, Continuous(years)PRT-2761 0.5%PRT-2761 1%PatanolPRT-2761 0%Total
Median52 ± 14.4949 ± 12.9846 ± 10.8152 ± 9.2150 ± 12.98
Sex: Female, Male
Sex: Female, Male(Participants)PRT-2761 0.5%PRT-2761 1%PatanolPRT-2761 0%Total
Female2412161567
Male817141453
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PRT-2761 0.5%PRT-2761 1%PatanolPRT-2761 0%Total
Hispanic or Latino393520
Not Hispanic or Latino29202724100
Unknown or Not Reported00000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PRT-2761 0.5%PRT-2761 1%PatanolPRT-2761 0%Total
American Indian or Alaska Native00011
Asian00000
Native Hawaiian or Other Pacific Islander00011
Black or African American30249
White29272723106
More than one race01102
Unknown or Not Reported01001
Region of Enrollment
Region of Enrollment(participants)PRT-2761 0.5%PRT-2761 1%PatanolPRT-2761 0%Total
United States32293029120
Iris Color
Iris Color(Participants)PRT-2761 0.5%PRT-2761 1%PatanolPRT-2761 0%Total
Black00022
Blue10128636
Brown1312151757
Hazel445114
Green512311
Average Post-CAC Itching Score at Baseline
Average Post-CAC Itching Score at Baseline(Participants)PRT-2761 0.5%PRT-2761 1%PatanolPRT-2761 0%Total
≤ 2.5756523
> 2.52524242497

2 further baseline measures are reported on the registry.

08

Study locations

1 site
  • Andover Eye Associates
    Andover, Massachusetts 01810, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2017 to primary completion in Feb 2018, 4 months.

Results were first posted in Oct 2022, 4 years 8 months after primary completion. A results delay was requested in Aug 2020.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 19, 2017
First posted
Oct 25, 2017
StartActual
Oct 13, 2017
Primary completionActual
Feb 16, 2018
CompletionActual
Feb 18, 2018
Results delay requested
Aug 19, 2020
Results first posted
Oct 17, 2022
Last update
Oct 17, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 17, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03320434
Lead sponsor
ORA, Inc.
Responsible party
Sponsor
First posted
Oct 25, 2017
Start date
Oct 13, 2017
Primary completion
Feb 16, 2018
Completion
Feb 18, 2018
Results posted
Oct 17, 2022
Last update
Oct 17, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion